Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Capecitabine with cyclophophamide as maintenance therapy in advanced colorectal cancer patients

ABSTRACT: Primary outcome(s): In phase I the OBD of capecitabine would be identified using response assessment criteria RECIST version 1.1 and flow cytometry measurement of CEC. So, a twin primary endpoints of clinical benefit rate at 2 months ( CR or PR or SD persisting till 2 months) and proportional decline in CEC will be used for determination of OBD. Timepoint: 30 months

DISEASE(S): Malignant Neoplasm Of Rectum

PROVIDER: 2714393 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Phase Fase II examination of irinotecan, cetuximab and everolimus for patients resistente to chemoptherapy with metastatic colorectal cancer and KRAS mutation or with KRAS wildtype after progression on therapy with irinotecan og cetuximab – effect and biological markers.

Project description:Main objective: • Disease control as the sum of number of patients with CR, PR and SD. Primary endpoints: Disease control as sum of number of patients with CR, PR, and SD

| 2527155 | ecrin-mdr-crc

Trancription profling of In-transit extremity melanoma II lesions

Project description:An evaluation of biopsies from patients with in-transit extremity melanoma who have been treated with melphalan in the setting of isolated limb infusion Gene expression profiles were obtained from 52 lesions across 28 patients and evaluated for expression values that correlated with response to melphalan isolated limb infusion Chemotherapy response analysis: complete response - CR; partial response - PR; stable disease - SD; progressive disease - PD. 52 samples.

2010-03-09 | E-GEOD-19293 | biostudies-arrayexpress

Lung cancer metabolomics analysis

Project description:This study explored models predictive of staging and chemotherapy response based on metabolomic analysis of fresh, patient-derived non-small cell lung cancer (NSCLC) core biopsies. Prospectively collected tissue samples before initial treatment were evaluated with high-resolution 2DLC-MS/MS and 13C-glucose enrichment, and the data were comprehensively analyzed with machine learning techniques. Patients were categorized as Disease-Control (DC) [encompassing complete-response (CR), partial-response (PR), and stable-disease (SD)] and Progressive-Disease (PD). Four major types of learning methods (partial least squares discriminant analysis (PLS-DA), support vector machines (SVM), artificial neural networks, and random forests) were applied to differentiate between positive (DC and CR/PR) and poor (PD and SD/PD) responses, and between stage I/II/III and stage IV disease. Models were trained with forward feature selection based on variable importance and tested on validation subsets.

2020-09-16 | ST001527 | MetabolomicsWorkbench

In-transit extremity melanoma III

Project description:An evaluation of biopsies from patients with in-transit extremity melanoma who have been treated with melphalan in the setting of isolated limb infusion or isolated limb perfusion. Gene expression profiles were obtained from 21 lesions across 19 patients and evaluated for expression that correlated with response to melphalan isolated limb infusion. Chemotherapy response analysis: complete response - CR; partial response - PR; stable disease - SD; progressive disease - PD; not evaluable - n.e.

2011-12-22 | E-GEOD-34599 | biostudies-arrayexpress

Effect of intestinal microbiome diversity on the efficacy and survival of chemotherapy for advanced non-small cell lung cancer

Project description:Interventions: Response Group:none;None Response Group:Nil Primary outcome(s): CR;PR;SD;PD;PFS;OS;Gut microbiome;Fecal metabolomics;Immune factor Study Design: Factorial

| 2689133 | ecrin-mdr-crc

Effects of intestinal microbiome diversity on the efficacy and survival of chemotherapy combined with immunotherapy and immunotherapy in advanced non-small cell lung cancer

Project description:Interventions: Group 1:Chemotherapy combined with immunotherapy;Group 2:Immunotherapy Primary outcome(s): CR;PR;SD;PD;PFS;OS;Gut microbiome;Fecal metabolomics;Immune factor Study Design: Non randomized control

| 2689155 | ecrin-mdr-crc

Efficacy and Safety of T Cell Receptor Modified T (TCR-T) Cells in Advanced Pancreatic Cancer, Lung Cancer and Colorectal Cancer Therapy

Project description:Interventions: experimental group:TCR-T treatment Primary outcome(s): complete response (CR);partial response (PR);stable disease (SD);progressive disease (PD);objective response rate (ORR);duration of response (DOR);tumor marker (TM);dose limited toxicity (DLT);markers of infection Study Design: Single arm

| 37438 | ecrin-mdr-crc

Expression data from BM-CD138+, obtained from newly diagnosed Multiple Myeloma patients [response to VTD therapy]

Project description:The prime focus of the current therapeutic strategy for Multiple Myeloma (MM) is an early and deep tumour burden reduction; this characterizes and defines the complete response (CR). To date, no description of the characteristics of the plasma cells (PC) prone to achieve CR has been reported. This study aimed at the molecular characterization of PC derived from MM patients who achieved CR after bortezomib-thalidomide-dexamethasone (VTD) first line therapy. One hundred and eighteen MM primary tumours obtained from homogeneously treated patients were globally profiled both for gene expression and for single nucleotide polymorphism genotype. Genomic results were used to obtain a predictor of sensitivity to VTD induction therapy, as well as to describe both the transcription and the genomic profile of PC derived from patients with MM who will respond optimally to primary induction therapy. By analysing the gene profiles of CR patients, we identified a 5-gene signature predicting CR with an overall median accuracy of 75% (range: 72%-85%). In addition, we highlighted the differential expression of a series of genes, whose deregulation, accordingly to their reported functions, might explain the CR patientsâ sensitivity to VTD therapy. We also showed that a small copy number loss, covering 606Kb on chromosome 1p22.1 was the most significantly associated with CR patients. The study provides insights into the genomic landscape of PC obtained from newly diagnosed MM patients achieving CR after VTD and shows that patients might be accurately stratified according to their sensitivity to VTD. 118 samples have been analyzed; the homogeneity of samples has been ensured by the immunomagnetic enrichment procedure: only >90% pure CD138+ cells have been employed. Response to vtd therapy (provided in each sample record); CR: complete response nCR: near complete response VGPR: Very good partial response PR: partial response SD: Stable disease

2015-12-31 | E-GEOD-68871 | biostudies-arrayexpress

Clinical trial of umbilical cord blood NK cell transfusion combined with PD-1 inhibitor for treatment of multiple solid tumors

Project description:Interventions: Group 1:PD-1 inhibitor by Intravenous infusion;Group 2:Intravenous infusion of PD-1 inhibitor (200mg) and UCBNK cells (5×10E6- 5×10E7/kg) the next day Primary outcome(s): objective remission rate (CR, PR, SD, PD) Study Design: Non randomized control

| 2690767 | ecrin-mdr-crc

Phase 1/2a study to evaluate the safety, activity, and pharmacokinetics of escalating doses of GNS561 in patients with primary or secondary liver cancer

Project description:Primary objectives: Phase 1:• To characterize the safety and tolerability of GNS561• To identify the recommended Phase 2 dose (RD) • To characterize the PK of GNS561 Phase 2a:• To characterize the safety and tolerability of GNS561 • To identify evidence of antitumor activity (tumor control rate : overall response rate + SD by RECIST 1.1) Primary endpoints: Safety:• Incidence and nature of DLTs by dose level during the 4 week dose escalation phase• Incidence, nature, and severity of adverse events• Change in vital signs, clinical laboratory (chemistry and hematology) values, urinalysis, electrocardiogram (ECGs) Efficacy:• Response rate (CR+ PR) • Disease control rate (CR+PR+SD)• Progression free survival Pharmacokinetics:• GNS561 PK over first 48 hours following first and repeated dose in Cycle 1 and Cycle 2

| 2537358 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data